Angiopep-2 Modified Exosomes Load Rifampicin with Potential for Treating Central Nervous System Tuberculosis

References

• Schaller MA, Wicke F, Foerch C, Weidauer S. Central nervous system tuberculosis: etiology, clinical manifestations and neuroradiological features. Clin Neuroradiol. 2019;29(1):3–18. doi:10.1007/s00062-018-0726-9
   PubMed Web of Science ®Google Scholar
• Leonard JM. Central nervous system tuberculosis. Microbiol Spectr. 2017;5:2. doi:10.1128/microbiolspec.TNMI7-0044-2017
   Web of Science ®Google Scholar
• Manyelo CM, Solomons RS, Walzl G, Chegou NN. Tuberculous meningitis: pathogenesis, immune responses, diagnostic challenges, and the potential of biomarker-based approaches. J Clin Microbiol. 2021;59:3. doi:10.1128/JCM.01771-20
   Web of Science ®Google Scholar
• Ruiz-Bedoya CA, Mota F, Tucker EW, et al. High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis. J Clin Invest. 2022;132:6. doi:10.1172/JCI155851
   Web of Science ®Google Scholar
• Tucker EW, Guglieri-Lopez B, Ordonez AA, et al. Noninvasive (11) C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci Transl Med. 2018;10:470. doi:10.1126/scitranslmed.aau0965
   Web of Science ®Google Scholar
• Savic RM, Ruslami R, Hibma JE, et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015;98(6):622–629. doi:10.1002/cpt.202
   PubMed Web of Science ®Google Scholar
• Marcianes P, Negro S, Garcia-Garcia L, Montejo C, Barcia E, Fernandez-Carballido A. Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis. Int J Nanomedicine. 2017;12:1959–1968. doi:10.2147/IJN.S130908
   PubMed Web of Science ®Google Scholar
• Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. doi:10.1016/j.biomaterials.2019.119491
   PubMed Web of Science ®Google Scholar
• Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38(6):754–763. doi:10.1038/aps.2017.12
   PubMed Web of Science ®Google Scholar
• Yang B, Chen Y, Shi J. Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms. Adv Mater. 2019;31(2):e1802896. doi:10.1002/adma.201802896
   PubMed Web of Science ®Google Scholar
• Shao J, Zaro J, Shen Y. Advances in exosome-based drug delivery and tumor targeting: from tissue distribution to intracellular fate. Int J Nanomedicine. 2020;15:9355–9371. doi:10.2147/IJN.S281890
   PubMed Web of Science ®Google Scholar
• Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–3195. doi:10.7150/thno.52570
   PubMed Web of Science ®Google Scholar
• Hu Y, Li X, Zhang Q, et al. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. Bioact Mater. 2021;6(9):2905–2913. doi:10.1016/j.bioactmat.2021.02.014
   PubMed Web of Science ®Google Scholar
• Ding Y, Wang L, Li H, et al. Application of lipid nanovesicle drug delivery system in cancer immunotherapy. J Nanobiotechnology. 2022;20(1):214. doi:10.1186/s12951-022-01429-2
   PubMed Web of Science ®Google Scholar
• Mustapic M, Eitan E, Werner JK Jr, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278. doi:10.3389/fnins.2017.00278
   PubMed Web of Science ®Google Scholar
• Saint-Pol J, Gosselet F, Duban-Deweer S, Pottiez G, Karamanos Y. Targeting and crossing the blood-brain barrier with extracellular vesicles. Cells. 2020;9:4. doi:10.3390/cells9040851
   Web of Science ®Google Scholar
• Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug delivery systems. J Control Release. 2021;329:894–906. doi:10.1016/j.jconrel.2020.10.020
   PubMed Web of Science ®Google Scholar
• Tian T, Zhang HX, He CP, et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018;150:137–149. doi:10.1016/j.biomaterials.2017.10.012
   PubMed Web of Science ®Google Scholar
• Jia G, Han Y, An Y, et al. NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo. Biomaterials. 2018;178:302–316. doi:10.1016/j.biomaterials.2018.06.029
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang Y, Chen X, et al. Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB. Biochem Biophys Res Commun. 2021;534:902–907. doi:10.1016/j.bbrc.2020.10.076
   PubMed Web of Science ®Google Scholar
• Shi XX, Miao WM, Pang DW, et al. Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. Biomater Sci. 2020;8(5):1290–1297. doi:10.1039/C9BM01750J
   PubMed Web of Science ®Google Scholar
• He C, Zhang Z, Ding Y, et al. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. J Nanobiotechnology. 2021;19(1):29. doi:10.1186/s12951-020-00751-x
   PubMed Web of Science ®Google Scholar
• Xunian Z, Kalluri R. Biology and therapeutic potential of mesenchymal stem cell-derived exosomes. Cancer Sci. 2020;111(9):3100–3110. doi:10.1111/cas.14563
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405. doi:10.1016/j.jconrel.2015.07.030
   PubMed Web of Science ®Google Scholar
• Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–858. doi:10.1002/stem.2575
   PubMed Web of Science ®Google Scholar
• Li XH, Zhang J, Li DF, Wu W, Xie ZW, Liu Q. Physiological and pathological insights into exosomes in the brain. Zool Res. 2020;41(4):365–372. doi:10.24272/j.issn.2095-8137.2020.043
   PubMed Web of Science ®Google Scholar
• Cho CF, Wolfe JM, Fadzen CM, et al. Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun. 2017;8:15623. doi:10.1038/ncomms15623
   PubMed Web of Science ®Google Scholar
• Hu L, Wang Y, Zhang Y, et al. Angiopep-2 modified PEGylated 2-methoxyestradiol micelles to treat the PC12 cells with oxygen-glucose deprivation/reoxygenation. Colloids Surf B Biointerfaces. 2018;171:638–646. doi:10.1016/j.colsurfb.2018.08.009
   PubMed Web of Science ®Google Scholar
• Revollo L, Kading J, Jeong SY, et al. N-cadherin Restrains PTH Activation of Lrp6/β-catenin Signaling and Osteoanabolic Action. J Bone Miner Res. 2019;34(11):2163–2165. doi:10.1002/jbmr.3845
   PubMed Web of Science ®Google Scholar
• Ding Y, Yang R, Yu W, et al. Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer. J Nanobiotechnology. 2021;19(1):147. doi:10.1186/s12951-021-00891-8
   PubMed Web of Science ®Google Scholar
• Roberts-Dalton HD, Cocks A, Falcon-Perez JM, et al. Fluorescence labelling of extracellular vesicles using a novel thiol-based strategy for quantitative analysis of cellular delivery and intracellular traffic. Nanoscale. 2017;9(36):13693–13706. doi:10.1039/C7NR04128D
   PubMed Web of Science ®Google Scholar
• Liu Y, Zou Y, Feng C, et al. Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma RNAi therapy. Nano Lett. 2020;20(3):1637–1646. doi:10.1021/acs.nanolett.9b04683
   PubMed Web of Science ®Google Scholar
• Hu Y, Wu X, Luo J, et al. Detection of pyrazinamide resistance of Mycobacterium tuberculosis using nicotinamide as a surrogate. Clin Microbiol Infect. 2017;23(11):835–838. doi:10.1016/j.cmi.2017.03.028
   PubMed Web of Science ®Google Scholar
• Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013;65(3):336–341. doi:10.1016/j.addr.2012.07.001
   PubMed Web of Science ®Google Scholar
• Geeurickx E, Tulkens J, Dhondt B, et al. The generation and use of recombinant extracellular vesicles as biological reference material. Nat Commun. 2019;10(1):3288. doi:10.1038/s41467-019-11182-0
   PubMedGoogle Scholar
• Melzer C, Rehn V, Yang Y, Bahre H, von der Ohe J, Hass R. Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells. Cancers. 2019;11:6. doi:10.3390/cancers11060798
   Web of Science ®Google Scholar
• Shen Y, Pi Z, Yan F, et al. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts. Int J Nanomedicine. 2017;12:5613–5629. doi:10.2147/IJN.S136401
   PubMed Web of Science ®Google Scholar
• de Castro RR, Do Carmo FA, Martins C, et al. Clofazimine functionalized polymeric nanoparticles for brain delivery in the tuberculosis treatment. Int J Pharm. 2021;602:120655. doi:10.1016/j.ijpharm.2021.120655
   PubMedGoogle Scholar
• de Jong B, Barros ER, Hoenderop JGJ, Rigalli JP. Recent advances in extracellular vesicles as drug delivery systems and their potential in precision medicine. Pharmaceutics. 2020;12:11. doi:10.3390/pharmaceutics12111006
   Web of Science ®Google Scholar
• Huo C, Xiao J, Xiao K, et al. Pre-treatment with zirconia nanoparticles reduces inflammation induced by the Pathogenic H5N1 influenza virus. Int J Nanomedicine. 2020;15:661–674. doi:10.2147/IJN.S221667
   PubMed Web of Science ®Google Scholar
• Zhu L, Sun HT, Wang S, et al. Isolation and characterization of exosomes for cancer research. J Hematol Oncol. 2020;13(1):152. doi:10.1186/s13045-020-00987-y
   PubMed Web of Science ®Google Scholar
• Díaz-Perlas C, Oller-Salvia B, Sánchez-Navarro M, Teixidó M, Giralt E. Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport. Chem Sci. 2018;9(44):8409–8415. doi:10.1039/C8SC02415D
   PubMed Web of Science ®Google Scholar
• Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003–2014. doi:10.1007/s11095-014-1593-y
   PubMed Web of Science ®Google Scholar
• Matsumoto J, Stewart T, Banks WA, Zhang J. The transport mechanism of extracellular vesicles at the blood-brain barrier. Curr Pharm Des. 2017;23(40):6206–6214. doi:10.2174/1381612823666170913164738
   PubMed Web of Science ®Google Scholar
• Yang X, Shi G, Guo J, Wang C, He Y. Exosome-encapsulated antibiotic against intracellular infections of methicillin-resistant Staphylococcus aureus. Int J Nanomedicine. 2018;13:8095–8104. doi:10.2147/IJN.S179380
   PubMed Web of Science ®Google Scholar
• Zong J, Pollack GM. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther. 2003;306(2):556–562. doi:10.1124/jpet.103.049452
   PubMed Web of Science ®Google Scholar
• Gupta D, Liang X, Pavlova S, et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J Extracell Vesicles. 2020;9(1):1800222. doi:10.1080/20013078.2020.1800222
   PubMed Web of Science ®Google Scholar
• Naftalin CM, Verma R, Gurumurthy M, et al. Coadministration of allopurinol to increase antimycobacterial efficacy of pyrazinamide as evaluated in a whole-blood bactericidal activity model. Antimicrob Agents Chemother. 2017;61:10. doi:10.1128/AAC.00482-17
   Web of Science ®Google Scholar
• Fang SB, Zhang HY, Wang C, et al. Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. J Extracell Vesicles. 2020;9(1):1723260. doi:10.1080/20013078.2020.1723260
   PubMed Web of Science ®Google Scholar
• Kimiz-Gebologlu I, Oncel SS. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022;347:533–543. doi:10.1016/j.jconrel.2022.05.027
   PubMed Web of Science ®Google Scholar
• Abhange K, Makler A, Wen Y, et al. Small extracellular vesicles in cancer. Bioact Mater. 2021;6(11):3705–3743. doi:10.1016/j.bioactmat.2021.03.015
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kim MS. Development and regulation of exosome-based therapy products. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(5):744–757. doi:10.1002/wnan.1395
   PubMed Web of Science ®Google Scholar
• David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv Drug Deliv Rev. 2017;119:120–142. doi:10.1016/j.addr.2017.05.006
   PubMed Web of Science ®Google Scholar
• Wen S, Dooner M, Papa E, et al. Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a radiation injury bone marrow murine model. Int J Mol Sci. 2019;20:21. doi:10.3390/ijms20215468
   Web of Science ®Google Scholar
• Fabbri M. Natural killer cell-derived vesicular miRNAs: a new anticancer approach? Cancer Res. 2020;80(1):17–22. doi:10.1158/0008-5472.CAN-19-1450
   PubMed Web of Science ®Google Scholar